IntelligenceQ today announced the public beta of GyaniMed™, its AI-driven process intelligence platform built for enterprise pharma teams. The release brings a coordinated desktop and web experience to accelerate compliant process automation across quality, regulatory, and manufacturing operations.
Beta users gain secure workspace orchestration, role-based copilots for QA and tech-transfer tasks, and knowledge-graph powered traceability to tighten audit readiness. Early partners are piloting GyaniMed™ to reduce deviations, improve handoffs, and shorten validation cycles with AI-generated, document-backed context.
The beta focuses on enterprise readiness: on-prem and VPC deployment options, managed encryption and key rotation, SOC2-aligned logging, and granular data residency controls. IntelligenceQ is working with design partners across the US and UK to expand connectors into common MES, LIMS, and eQMS systems.
“Process intelligence must be auditable by design. Our beta brings AI into pharma operations with the guardrails enterprises expect — lineage, approvals, and policy-aware agents that stay within compliance boundaries.”
— Dr. Swapnil Khadke, co-founder and CEO
Beta highlights
- Desktop and web apps with shared secure contexts
- Role-focused copilots for QA, QC, and manufacturing support
- Traceable AI outputs with linked source documents
- Configurable data residency, encryption, and audit logging
Availability
GyaniMed™ public beta is open to new design partners starting today and can request access at gyanimed.com.